ABVC PE Ratio & Valuation, Is ABVC Overvalued

Historical Valuation

ABVC Biopharma Inc (ABVC) is now in the Fair zone, suggesting that its current forward PS ratio of 12.37 is considered Fairly compared with the five-year average of -4.15. The fair price of ABVC Biopharma Inc (ABVC) is between 0.80 to 1.75 according to relative valuation method.

Relative Value

Fair Zone

0.80-1.75

Current Price：1.30

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is ABVC Biopharma Inc (ABVC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

ABVC Biopharma Inc (ABVC) has a current Price-to-Book (P/B) ratio of 4.26. Compared to its 3-year average P/B ratio of 1.45, the current P/B ratio is approximately 192.96% higher. Relative to its 5-year average P/B ratio of 8.78, the current P/B ratio is about -51.45% higher. ABVC Biopharma Inc (ABVC) has a Forward Free Cash Flow (FCF) yield of approximately -4.40%. Compared to its 3-year average FCF yield of -31.02%, the current FCF yield is approximately -85.83% lower. Relative to its 5-year average FCF yield of -26.36%, the current FCF yield is about -83.32% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ABVC competitors is 14.75, providing a benchmark for relative valuation. ABVC Biopharma Inc Corp (ABVC.O) exhibits a P/S ratio of 12.37, which is -16.11% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ABVC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ABVC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ABVC currently overvalued or undervalued?

What is ABVC Biopharma Inc (ABVC) fair value?

ABVC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ABVC Biopharma Inc (ABVC) is between 0.80 to 1.75 according to relative valuation method.

How does ABVC's valuation metrics compare to the industry average?

The average P/S ratio for ABVC's competitors is 14.75, providing a benchmark for relative valuation. ABVC Biopharma Inc Corp (ABVC) exhibits a P/S ratio of 12.37, which is -16.11% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for ABVC Biopharma Inc (ABVC) as of Mar 17 2026?

As of Mar 17 2026, ABVC Biopharma Inc (ABVC) has a P/B ratio of 4.26. This indicates that the market values ABVC at 4.26 times its book value.

What is the current FCF Yield for ABVC Biopharma Inc (ABVC) as of Mar 17 2026?

As of Mar 17 2026, ABVC Biopharma Inc (ABVC) has a FCF Yield of -4.40%. This means that for every dollar of ABVC Biopharma Inc's market capitalization, the company generates -4.40 cents in free cash flow.

What is the current Forward P/E ratio for ABVC Biopharma Inc (ABVC) as of Mar 17 2026?

As of Mar 17 2026, ABVC Biopharma Inc (ABVC) has a Forward P/E ratio of -0.48. This means the market is willing to pay $-0.48 for every dollar of ABVC Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ABVC Biopharma Inc (ABVC) as of Mar 17 2026?

As of Mar 17 2026, ABVC Biopharma Inc (ABVC) has a Forward P/S ratio of 12.37. This means the market is valuing ABVC at $12.37 for every dollar of expected revenue over the next 12 months.

ABVC Valuation